RDHL.US Redhill Biopharma Ltd

Healthcare Pharmaceuticals USA Stocks
0.3600 USD
Close of Nov 17, 2026
0.3414 1.42
Market cap
USD 3.20M
P/E
-
P/B
1.01x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is RDHL.US undervalued?

Graham number

The Graham number of Redhill Biopharma Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Redhill Biopharma Ltd fundamental analysis

No fundamental analysis for Redhill Biopharma Ltd yet.

Redhill Biopharma Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Redhill Biopharma Ltd

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prosta…

Full company profile